Non-small cell lung cancer metastatic

• A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting
  2023-503376-24-00 5 2024-03-20 "Metastatic non-small cell lung cancer (NSCLC)"
• A Master rollover study to provide continued access to, and assess, long term safety of the study drugs. Recruiting
  2023-506330-73-00 5 2024-03-13 "Advanced (unresectable or metastatic) human epidermal growth"
• A study to look at how safe divarasib is when given on its own or in combination with other anti-cancer therapies, and how well these medici … Recruiting
  2023-507171-22-00 9 2023-06-21 "Untreated Advanced or Metastatic Non-Small Cell Lung Cancer"
• A study investigating the use of EP0031 in patients with cancers having an abnormal RET gene. Recruiting
  2022-501636-42-00 9 2023-03-21 "Advanced RET-altered malignancies"
• MK-2870 versus Chemotherapy in Previously Treated or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other … Recruitment ended
  2023-503539-16-00 5 2025-11-11 "Non-small Cell Lung Cancer (NSCLC)"
• A Study of Subcutaneous Nivolumab plus Intravenous Ipilimumab and Chemotherapy in Participants with Previously Untreated Metastatic or Recur … Recruitment ended
  2024-520108-25-00 4 2025-11-05 "Non-small cell lung cancer (NSCLC)"
• Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer Recruitment ended
  2025-521115-40-00 4 2025-09-30 "Advanced or Metastatic Non-small Cell Lung Cancer"
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Recruitment ended
  2024-517818-15-00 9 2025-06-06 "Non-Small Cell Lung Cancer"
• A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in Advanced NSCLC (PULMO-01) Recruitment ended
  2024-517741-14-00 9 2025-04-22 "advanced non-squamous non-small cell lung cancer (NSCLC)"
• Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Recruitment ended
  2024-513621-23-00 5 2025-04-18 "Advanced/metastatic non-small cell lung cancer (NSCLC)"
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Recruitment ended
  2024-512998-27-00 5 2025-02-21 "Non-Small Cell Lung Cancer"
• Clinical Trial to compare subcutaneous pembrolizumab given with hyaluronidase to intravenous pembrolizumab in patients with newly diagnosed … Recruitment ended
  2024-513165-39-00 5 2024-11-11 "Participants With Metastatic Non-small Cell Lung Cancer With"
• A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive … Recruitment ended
  2024-510908-37-00 5 2024-08-28 "KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lun"
• ETOP 14-18 CHESS: Immunotherapy, chemotherapy and radiotherapy, followed by surgery or radiotherapy, for patients with newly diagnosed non-s … Recruitment ended
  2024-511134-12-00 4 2023-12-20 "NSCLC, synchronous oligo-metastatic"
• Clinical Study of Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) versus Intravenous Pembrolizumab, Given with Chemoth … Recruitment ended
  2022-501506-36-00 5 2023-04-11 "First-line treatment of participants with metastatic nonsmal"
• Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Recruitment ended
  2023-503501-11-00 5 2023-02-09 "Metastatic Non-small Cell Lung Cancer"
• Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Recruitment ended
  2023-509429-37-00 5 2022-10-03 "Advanced or Metastatic Non-Small Cell Lung Cancer"
• A Phase 1/2a study of PF-07220060 in Participants with Advanced Solid Tumors Recruitment ended
  2024-512120-11-00 7 2022-08-31 "Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cance"
• Study of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Given with Chemotherapy, to Treat Metastatic Squamous or Non Squamous … Recruitment ended
  2023-508308-40-00 5 2021-07-30 "Metastatic (stage IV) squamous or nonsquamous non-small cell"
• Phase 1/2 Study of CLN-081 in Patients with Lung Cancer Recruitment ended
  2024-516532-97-00 9 2020-03-26 "Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion "
• Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors Recruitment ended
  2023-503812-34-00 4 2019-02-13 "Locally Advanced or Metastatic Disease in Solid Tumors"
• Phase II umbrella study of novel anti-cancer agents in patients with NSCLC who progressed on an anti-PD-1/PD-L1 containing therapy. Recruitment ended
  2023-509004-15-00 10 2018-02-20 "Patients with non-small cell lung cancer (NSCLC)."
• Study with investigational drug PF-06463922 and comparator crizotinib in patients with a specific type of advanced lung cancer Recruitment ended
  2023-509169-19-00 5 2017-07-11 "Advanced ALK positive non-small cell lung cancer"
• eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Recruitment ended
  2024-513454-29-00 5 2015-10-15 "Non-Small Cell Lung Cancer (NSCLC)"

Showing 25–48 of 72 trials